Since the introduction of cisplatin to oncology in 1978, Pt(II) and Pd(II) compounds have been intensively studied with a view to develop the improved anticancer agents. Polynuclear polyamine complexes, in particular, have attracted special attention, since they were found to yield DNA adducts not available to conventional drugs (through long-distance intra-and interstrand cross-links) and to oen circumvent acquired cisplatin resistance. Moreover, the cytotoxic potency of these polyamine-bridged chelates is strictly regulated by their structural characteristics, which renders this series of compounds worth investigating and their synthesis being carefully tailored in order to develop third-generation drugs coupling an increased spectrum of activity to a lower toxicity. e present paper addresses the latest developments in the design of novel antitumor agents based on platinum and palladium, particularly polynuclear chelates with variable length aliphatic polyamines as bridging ligands, highlighting the close relationship between their structural preferences and cytotoxic ability. In particular, studies by vibrational spectroscopy techniques are emphasised, allowing to elucidate the structure-activity relationships (SARs) ruling anticancer activity.
Introduction
Cancer represents one of the major causes of death in humans worldwide, only overcome by cardiovascular diseases, and represents a huge burden on society (both sociologically and economically). About 20 million cancer cases are expected to occur in the next two decades, which renders the quest for new and improved antineoplastic agents (namely, based on natural compounds [1] ) an urgent issue in the �eld of Biomedicine and Human Health. Over the past decade, efforts have been made in the way of understanding the carcinogenesis process, which is recognised to consist in a progressive disorganisation at both the cellular and tissue levels. is knowledge is essential to develop new chemotherapeutic strategies, in order to control the incidence of the most recurrent cancer types.
While many drug molecules are "organic" in nature, other elements in the periodic table, particularly metals, offer a much more diverse chemistry and have important therapeutic applications [2] . e use of metal-based compounds as therapeutic drugs dates back to over 5000 years. In modern days, the study of organometallic pharmaceuticals started with the pioneering work of Köpf and Köpf-Maier (in the late 1970's), who investigated the antitumor activity of early transition metal cyclopentadienyl complexes [3] . Since the introduction of cisplatin (cis-dichlorodiammineplatinum(II), cisPt(Cl 2 (NH 3 ) 2 ) to oncology, in the 1970's, organometallic compounds have gained a progressively increasing interest in medicinal chemistry [4] [5] [6] [7] [8] [9] . Particularly in the treatment of malignant formations, inorganic compounds have had an enormous impact [7, [10] [11] [12] [13] [14] [15] , their activity relying mostly on speci�c interactions with DNA, leading to damage and ultimately to cell death. e development of inorganic anticancer agents is widening rapidly beyond platinum chemistry, encompassing a large variety of metal ions and ligands, and many diverse designs tailored according to the speci�c receptor or biological target. So far, the major classes of metal-based anticancer drugs include platinum(II) and platinum(IV), palladium(II), gold(I) and gold(III), ruthenium(II) and ruthenium(III), bismuth(III), rhenium(I), and copper(II) compounds, as well as gallium(III) and tin(IV) derivatives, some of them having been reported to demonstrate higher in vitro anticancer activity than cisplatin [16] . e design of metal-based anticancer drugs was thus initiated by cisplatin (cis-Pt(NH 3 ) 2 Cl 2 , Platinol, Figure 1) , one of the leading agents in clinical use [17] [18] [19] [20] [21] with a high cytotoxic effect upon a variety of tumour types, in particular against testicular, ovarian, head and neck, and bladder carcinomas, as well as lymphoma [22] [23] [24] [25] [26] [27] [28] [29] [30] . e therapeutic target of platinum complexes is DNA, via binding to the purine bases through 1,2-intrastrand cross-links, yielding one or more 1,2-d(GpG) and 1,2-d(ApG) bifunctional adducts in which the two chlorine atoms of the cisplatin molecules are replaced (upon hydrolysis) by N 7 atoms of adjacent purines [31] [32] [33] [34] . ese adducts activate several cellular processes that mediate cytotoxicity, namely, bending and unwinding of the double helix leading to the disruption of DNA duplication and inducing cell death by apoptosis [35] [36] [37] [38] [39] [40] .
e importance of platinum-based anticancer agents is re�ected by the fact that they are presently used in 50 to 70% of all chemotherapy schemes administered to cancer patients. However, the use of cisplatin and related drugs (secondgeneration carboplatin and third-generation oxaliplatin) is restricted by their dose-limiting deleterious side effects (e.g., nephro-and hepatotoxicity) and by acquired resistance upon prolonged administration [41] [42] [43] [44] [45] , as well as by their lack of e�ciency against many cancer types, speci�cally metastatic ones. Hence, one of the main challenges in the rational design of metal-containing chemotherapy agents is to enhance their cytostatic activity while simultaneously reducing toxicity [7, 15, [46] [47] [48] [49] [50] [51] [52] [53] . Crucial progress encompasses the elucidation of mechanisms of tumour resistance to these drugs, the introduction of new platinum agents (e.g., picoplatin and satraplatin), the development of combination therapeutic schemes with speci�c resistance modulators, and novel targeting strategies (liposomal formulations and nanodelivered drugs).
Based on the substantial expertise acquired on metalbased (both organometallic and inorganic) anticancer drugs for the last thirty years, with a special emphasis on their interaction with particular receptors and protein targets associated with tumour malignancy, it is reasonable to expect that innovative agents capable of modifying cell behaviour and cancer growth will be discovered [54] . In fact, carefully designed platinum and palladium complexes structurally different from cisplatin and its second-generation analogues are prone to display an altered spectrum of clinical activity and toxicity, due to differences in cellular biochemical pharmacology [53] . erefore, the parameters ruling their cytotoxicity may not follow the patterns applied to cisplatinlike agents. A tailored drug design and drug repro�ling (rational modi�cation of known drugs [55] ) envisage an improved cytostatic activity, optimised modes of delivery, and reduced toxicity and acquired resistance. Somewhat disappointingly, however, from thousands of compounds tested only about 20 new drugs have entered clinical trials since the discovery of cisplatin [49, 51, [56] [57] [58] . Actually, it is estimated that more than 10000 compounds need to be screened in order to achieve one new successful anticancer drug. e present paper accounts for the latest developments in the design of novel antitumor agents based on palladium and platinum with amine ligands, particularly polynuclear chelates with aliphatic polyamines as bridging linkers (e.g., biogenic polyamines). Special emphasis is placed on the close relationship between the compound's structural and conformational preferences, and their cellular uptake, biodistribution, and ability to affect DNA.
Linear Polyamines as Ligands
Amines are suitable chelating ligands for transition metal ions such as platinum, yielding stable, and reasonably water soluble coordination compounds. Linear aliphatic amines, in particular, are recognised to have a high conformational freedom and may be designed to display suitable �exibility and polidenticity features, which constitutes an advantage for an efficient interaction with metal ions and biological receptors. e conformational preferences of alkylamines depend on different factors, from steric, dipolar, and hyperconjugative effects to the relative importance of intra versus intermolecular interactions, namely, hydrogen-bond type close contacts [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] .
In particular, the biogenic polyamines (PAs) (Figure 2 ) are physiological polycations essential for cell growth and differentiation and recognised to be closely related to neoplastic processes [2, 73, 74] . Also, modi�ed biogenic polyamines have been synthesised in view of their use in cancer chemotherapy [75] [76] [77] , either symmetrically or unsymmetrically alkylated, at the terminal and/or central nitrogens (e.g., ethyl-substituted spermine, BENSpm, Figure  2 ), conformationally restricted (e.g., by addition of cyclic and/or aromatic moieties), or differing in the N-to-N alkyl bridges. In fact, structural changes at the terminal amines of linear PAs are known to drastically affect their biological activity, which relies mostly on these molecular moieties. Additionally, this type of chemical modi�cation has been shown to affect the regulatory paths associated with biogenic PA biosynthesis, catabolism, and transport, through a Trojan horse mechanism. e cell recognises these polyamine analogues as natural polyamines, and they are promptly taken up and accumulated to high levels, stimulating PA catabolism while inhibiting the cellular uptake of biogenic PAs (thus lowering the intracellular polyamine pool) [78] .
Apart from being potential modulators of polyamine function, this type of linear polyamines can act as multidentate ligands with a considerable affinity for both Pt(II) and Pd(II) ions. Linkage of some of these molecules to previously tested anticancer drugs (such as cisplatin)-yielding monoor polynuclear chelates-has been reported to lead to an enhancement of their cytotoxic effect [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] . In fact, the high conformational freedom and the dual hydrophiliclipophilic character of the polyamine ligands, comprising both cationic amine and imine groups and variable length hydrophobic alkyl linkers, allow these metal complexes to interact with DNA through a nonconventional way, both covalently (through direct binding of the metal centre to the purine bases) and noncovalently (via hydrophobic and hydrogen-bonding close contacts) ( Table 1) . e hydrophobic bridging moiety can interact with the DNA minor groove prior to covalent bond formation, and this preassociation affects the kinetics of crosslink formation as well as the local structure of the resulting adducts [89] . Additionally, the kinetics of this type of noncovalent interactions is rapid, taking place once the compounds enter the cell, as compared to the considerably slower covalent binding of the metal to DNA. Furthermore, the presence of nitrogen donor groups assists the molecular recognition of the drug by the polyphosphate backbone of DNA and related targets, due to the formation of favourable (N)H⋯O interactions. Additionally, the amphiphilic nature of the amine linkers, coupled to a charge dispersion along their carbon backbone, may result in an enhanced cellular uptake of the drug. e hydrophiliclipophilic balance in this kind of metal polyamine complexes depends on the relationship between the length of the carbon bridging chains and the number of coordinating amine/imine moieties and metal centres. Substituted polyamines (e.g., aminocarboxylic [90] or ethylenediamine esters [91, 92] to both Pt(II) and Pd(II) [90] and to act as modulators of the hydrophilic/lipophilic properties of the resulting chelates (thus improving their administration and bioavailability). e dimensions and �exibility of the alkylamine linkers also determine the type of DNA interplay, usually allowing longrange and interstrand interactions as opposed to mononuclear NH 3 -containing drugs such as cisplatin or carboplatin. Moreover, combination of linear polyamine ligands to distinct coordinating moieties-namely, aromatic groups such as phenyl, pyridyl [93] or bipyridyl [94] , selenium [95] , or sulphur-containing assemblies [96] -is oen used to improve antiproliferative ability, as well as to enhance selectivity and lower toxicity. Moreover, functionalization with biologically active molecules such as amino acids helps improving the antineoplastic ability [97] .
Platinum Amine Complexes as Chemotherapeutic Agents
Since the serendipitous discovery of the antitumor properties of cisplatin (cis-(diamminodichloro)platinum(II), cisPt(Cl 2 (NH 3 ) 2 , Figure 1 ) by Rosenberg et al. [17, 18] and its introduction to oncology, bioinorganic compounds have gained an increasing interest in the design of both therapeutic and diagnostic agents [21, 38, 49, 98] . Presently, platinum-based chemotherapeutics are among the most widely prescribed drugs in modern oncology (administered to ca. 50% of all cancer patients), either alone or in combination with other systemic compounds and/or radiation therapy. ey are known to be active in a wide range of solid tumours, including lung, head and neck, colon, bladder, ovarian, and testicular. is type of compounds exert their cytotoxic action through speci�c interactions with DNA [98] [99] [100] , covalent binding, the nitrogen in position 7 of guanine being the preferential platination site, followed by adenine's N 7 ( Figure 3 , Table 1 ). DNA crosslinking due to formation of these stable adducts (both intra-and interstand) leads to distorted conformations (either A or Z) relative to the native B form and triggers apoptosis, thus suppressing proliferation [49] .
Drugs in Clinical
Use. Despite the high number of studies in this �eld, only three platinum-based compounds are currently approved for clinical use: cisplatin, carboplatin, and oxaliplatin ( Figure 1 ) which comprise ammine (NH 3 ) or bidentate amine ligands and either chloride or carboxylate leaving groups. Nevertheless, apart from requiring intravenous administration, they are associated with severe side effects (e.g., nephrotoxicity, myelosuppression, ototoxicity, and neurotoxicity) as well as with acquired resistance, which strongly limits their application in the clinic.
Cisplatin. Since its approval for clinical use (in 1978), this square planar Pt(II) complex (cis-(diamminodichloro)platinum(II), trade name Platinol, Figure 1 ) has become one of the leading metal-based antineoplastic drugs and the �rst-line therapy for several human cancer types. Cisplatin damaging effect on DNA is due to short-range inter-and intrastrand cross-links (mainly at the double-helix purine bases) [38, 101, 102] . Unfortunately, it presents several major drawbacks, such as cumulative toxicities of nephrotoxicity and ototoxicity, and treatment-induced resistance, which has prompted the development of novel cisplatin-like agents.
Carboplatin. Carboplatin (cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II), approved in 1989, trade name Paraplatin, Figure 1 ) is a second-generation Pt(II) compound that differs from cisplatin by the presence of a bidentate dicarboxylate ligand as its leaving group instead of the more labile cisplatin's chlorides [103] . is renders the complex activation kinetics much slower in relative to cisplatin [104] and consequently leads to a signi�cantly lower toxicity, while yielding the same type of DNA adducts. e higher stability relative to cisplatin allows more time for the drug to reach the target molecule [12] , leading to a longer lasting effect: carboplatin has a retention half-life of 30 hours, as compared to 1.5-3.6 hours for cisplatin. Moreover, it presents reduced side-effects relative to cisplatin, particularly regarding nephrotoxicity (which is negligible), and was shown to be effective in some strains of cancer that are not responsive to cisplatin. Figure 1 ) is a Pt(II) complex comprising a bidentate 1,2-diaminocyclohexane stable ligand (instead of two monodentate ammine ligands) and an oxalate leaving group [105, 106] . Inclusion of the diaminocyclohexane moiety was intended to contribute to a larger cytotoxicity when compared to cisplatin and carboplatin (more damaging Pt-DNA adducts), as well as to avoid cross-resistance with those widely used drugs [107] . e particularly high activity of this third-generation agent, even in cisplatin-resistant tumour models, coupled to its decreased toxicity, prompted further studies on its use as a treatment option aer the failure of the cisplatin or carboplatin therapy.
Although oxaliplatin is typically administered in combination regimes (e.g., with �uorouracil and leucovorin) for the treatment of colorectal cancer, it is also being screened against advanced cancers such as gastric and ovarian. Presently, several oxaliplatin analogues are being synthesized and tested as to their cytotoxicity in comparison to oxaliplatin [108] [109] [110] , including dinuclear complexes comprising a cisplatin-like moiety [111] . ese have shown promising results, namely, identical cytotoxicity in ovarian cancer cells with signi�cantly higher tolerability. improved delivery (and consequently lower toxicity), ProLindac and Lipoplatin.
Agents in Advanced Clinical
Satraplatin. Satraplatin (bis-(acetato)amminedichloro(cyclohexylamine)platinum(IV), trade name Orplatna, Figure 4 ) is a third-generation Pt(IV) compound, structurally similar to cisplatin but comprising two axial acetate groups responsible for an improved oral bioavailability that renders satraplatin the �rst platinum agent susceptible of oral administration [112] . e lower reactivity of Pt(IV) as compared to Pt(II) is prone to diminish loss of active drug during the pharmacokinetic phase and to decrease the incidence of side reactions usually responsible for unwanted deleterious side effects. Satraplatin displays improved therapeutic properties compared to other platinum agents such as cisplatin, carboplatin, and oxaliplatin [48, [113] [114] [115] , namely, the potential to overcome platinum resistance [116] and the signi�cantly milder toxicity pro�le [117] . Additionally, since satraplatin is more hydrophobic than cisplatin or oxaliplatin, it has demonstrated efficacy in cisplatin-resistant tumours. Moreover, the lack of cross-resistance of taxane-resistant cells to satraplatin is of particular importance in cancers for which the former are standard chemotherapeutics (e.g., hormone-refractory prostate cancer).
Upon oral administration, satraplatin is rapidly metabolised into several (at least six) cisplatin analogues, by removal of the acetate moieties [115] . (cis-amminedichloro-(cyclohexylamine)-platinum(II)), the most abundant one, is rapidly absorbed through the gastrointestinal mucosa, reaching peak plasma levels within 2 hours. is metabolite binds to DNA through 1,2-intra-and interstrand crosslinks, leading to cell-cycle arrest at the G 2 phase and subsequent induction of apoptosis [118] . Both the administered agent and its metabolites are largely bound to blood constituents (e.g., plasma proteins), only a small percentage occurring as free platinum.
Satraplatin has overcome Phase III clinical trials, having shown great efficacy against several platinum-resistant human cancer cell lines [115, 116, 119] , including lung, ovary, cervix, and prostate (pivotal SPARC trial, Satraplatin and Prednisone Against Refractory Cancer [120, 121] ). Figure 4 ) is a sterically hindered Pt(II) mixed amine complex, designed to overcome glutathionemediated platinum resistance [122] [123] [124] . Since one of the amines is substituted by a bulkier group (2-methylpyridine or -picoline), glutathione competition occurs through a dissociative thiol substitution reaction instead of an associative one (as for cisplatin). is leads to a slower substitution kinetics, therefore unfavouring the glutathionemediated resistance mechanisms [125] . Picoplatin displays an improved safety compared to other platinum agents (particularly regarding nephro-and neurotoxicities) [114, 122, 126, 127] and has shown activity against cisplatin, carboplatin, and oxaliplatin-resistant cancer lines [126, 128] such as small cell lung, colorectal, and hormone-refractory prostate cancers.
e favourable results obtained for this experimental Pt(II)-drug (Phases I and II), speci�cally developed for the treatment of patients with solid tumours, pave the way for late-stage studies aiming at an anticancer activity similar to that of other platinum agents, such as oxaliplatin, combined to a lower toxicity and the ability to overcome resistance.
Studies on oral versus intravenous administration of picoplatin have demonstrated that it achieves linear and dosedependent plasma exposure when administered orally, yielding sufficient bioavailability to support further clinical studies [129] . Furthermore, oral picoplatin has shown signi�cant potential for use in combination therapies.
Liposomal and Polymer-Based Agents. Liposomal and polymer-conjugated drugs are known to display a better tolerance pro�le and a higher accumulation in the tumour environment. In fact, encapsulation of metal-based drugs in a liposome or linkage to a speci�cally designed polymer is quite successful strategy aimed at improving delivery, optimising the tumour response to treatment, and reducing systemic toxicity.
In these formulations, the drug-delivery vehicle complexes should obey a set of parameters in order to better attain the required goals: (i) solubility and biocompatibility with the physiological media; (ii) suitable composition, size/shape, and charge, to allow easy membrane permeation; coating with speci�c compounds (e.g., polyethylenoglycol (PEG)) is sometimes required to avoid rapid excretion; (iii) control of the rate and site of drug release; (iv) release of the intact drug from the delivery entity (without changes in the pharmacophore); (v) in vivo drug stability within the delivery cluster.
ProLindac. ProLindac is a nanopolymer-oxaliplatin conjugate where the active moiety of oxaliplatin [Pt(R,Rdiaminocyclohexane)] is bound to the hydrophilic biocompatible polymer HPMA (hydroxypropylmethacrylamide) (Figure 4) , which increases the drug's plasma clearance halftime. is polymeric entity acts both as a delivery and targeting vehicle, with a view to enhance the drug's bioavailability at the target due to a higher retention and better permeability [130, 131] . ProLindac undergoes decomposition-at the pH-sensitive Pt-polymer linker-thus releasing the pharmacophore, preferably at low pH [128, 132] . Since tumours are generally more acidic than the surrounding normal tissue, this constitutes a quite effective targeting strategy.
Clinical trials (Phase II) in a panel of cancer lines evidenced a higher efficacy when compared to carboplatin's or oxaliplatin's, coupled to an excellent tolerability (with no signs of acute neurotoxicity) [133, 134] . Actually, a signi�cantly greater tumour growth inhibition was observed in several models, including human breast, ovarian, lung, and prostate.
In addition to cytotoxicity against cisplatin-resistant cell lines, ProLindac also showed anticancer activity towards metastatic melanoma and advanced ovarian cancer [135] .
Lipoplatin. Several liposomal formulations of platinum agents have been developed in recent years: Lipoplatin (the liposomal-encapsulated cisplatin [136] [137] [138] [139] [140] ), Lipoxal (the liposomal formulation of oxaliplatin) [141] [142] [143] , and Aroplatin (a liposomal formulation of an oxaliplatin analogue) [144] [145] [146] .
Lipoplatin (Figure 4 ), which has a small particle size (from 90 to 130 nm), is able to cross cell membranes more easily than its guest molecule cisplatin and causes signi�cantly less deleterious side effects (almost negligible nephrotoxicity, ototoxicity, and neurotoxicity). Liposomeincluded cisplatin was found to be active against metastatic tumours, namely, refractory prostate cancer, as well as colon, gastric, and nonsmall cell lung cancers [147, 148] , through a mechanism similar to cisplatin's. Gastric cancer, in particular, displayed the highest levels of total platinum accumulation (up to 260 mg/g tissue) [149] .
Additionally, cisplatin encapsulated in polyethylene glycol-coated liposomes containing a new cationic lipid (TRX-20) were found to lead to an increased delivery of the platinum agent to some metastatic tumours (such as prostate cancer) [150] , which constitutes a very promising approach for increasing the drug's bioavailability at its target, and hence its effectiveness. e presence of a PEG coating, in particular, prevents drug detection by immunogenic entities and consequent rapid excretion [148] .
Lipoplatin has successfully overcome Phases I, II, and III human clinical trials [136, [151] [152] [153] [154] .
Polyamine-Bridged Polynuclear Complexes.
In the last two decades, mononuclear platinum complexes have given way to polynuclear compounds, comprising 2 or 3 metal centres ( Figure 5 ), expected to display a higher cytotoxicity due to a more severe (less repairable) DNA damage. Within these, polyamine-bridged polynuclear Pt(II) chelates have been introduced as promising anticancer agents by Farrell and coworkers [15] . ese new generation compounds, comprising di-, tri-, or tetranuclear-charged moieties and linear aliphatic polyamines as bridging ligands (Figure 6 ), induce an enhanced cytotoxic effect in comparison to the Pt-drugs currently approved for clinical use which comprise only one coordinating metal ion and are much more restricted conformationally. Actually, the cisplatin-like chelates have a distinct mechanism of action, being able to bind at several sites along the DNA helix simultaneously, through longrange intra-and interstrand cross-links are not accessible to classical platinum agents [15, 102, [155] [156] [157] [158] .
Several of these polyfunctional chelates using di-, tri-, and tetramines as linkers have been the object of intense research [26, 81, [159] [160] [161] [162] [163] [164] [165] [166] [167] , in view of developing novel anticancer agents with a broad spectrum of pharmacological activity, coupling an improved therapeutic pro�le to a lower toxicity, and hopefully overcoming acquired cisplatin and carboplatin resistance (Table 1) . e biogenic polyamines putrescine, spermidine, spermine, and their N-alkylated counterparts, in particular, have been used as bridging ligands, yielding Pt(II) and Pd(II) complexes differing in the geometry and coordination type of the metal centres ( to distinctive and very effective interactions with DNA [52, 160, [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] . In these chelates, designed to emphasize innovative modes of binding with DNA, two or three Pt(II) centers are tightly assembled by linear amine linkers, their biological activity being ruled by the diverse spacings and relative orientations of the metal ions' coordinating environment, according to speci�c structure-activity relationships (SARs). is kind of interplay, through nonconventional interactions, results in different types of drug-induced DNA lesions-at more than one base, interstrand and long range-responsible for a more severe damage, less easily repairable, which will be re�ected in a higher antineoplastic efficacy [158, 165-168, 175, 177, 183, 184] . Within this group of compounds, the set of polynuclear platinum complexes bridged by aliphatic diamines developed by Farrell and collaborators deserve special attention, since they constitute a unique class of potential anticancer agents with activity in cisplatin-resistant model systems [15, 81, 84-86, 159, 185-205] . eir DNA-binding pro�le produces an array of structurally distinct adducts, not available to mononuclear analogues such as cis-[PtCl 2 (NH 3 ) 2 ]. e possibility of triand tetrasubstitution inherent to the polynuclear structure opens interesting challenges for the design of agents capable of speci�c DNA binding. ese agents are expected to lead to a higher efficacy and speci�city regarding DNA binding (e.g., increased number of long-range interstrand cross-links, usually at more than one site along the double helix), each type of platinum structure displaying its own particular cytotoxic characteristics, which may therefore be varied in order to modulate DNA binding and activity. One such complex, triplatinum BBR3464 (Triplatin, [{trans- Figure 6 ) [89, 156, 159, 185, 187, 191, 199, [206] [207] [208] [209] [210] [211] [212] , was the only platinum compound not based on the cisplatin chemotype to have entered human clinical trials [15] . It showed very promising results, namely, towards melanoma, pancreatic, lung, and ovarian cancers, but it was discarded during Phase II clinical trials due to poor response rates [48] and severe toxicity (extensive metabolism and irreversible protein bonding in human plasma, Table 1 ) [184, 213] .
Apart from these polyamine-based coordinative compounds, affecting DNA through interaction modes typical of platinum agents-covalent groove binding-a novel approach was recently disguised, consisting in noncoordinative compounds that interact with DNA exclusively by noncovalent modes [186, 188, 189, 203, 214, 215] . ese innovative DNA-backbone binders do not contain hydrolysable groups, displaying positively charged NH 3 or "dangling" alkylamine moieties instead. TriplatinNC, an octacationic trinuclear platinum(
8+ , Figure 6 , Table 1 ), is the �rst reported Pt(II) antitumor complex that interacts with biomolecules solely in a noncoordinative fashion. While these compounds cannot yield covalent metal-purine base adducts, they associate with DNA through hydrogen bond and electrostatic interactions [163, 186-191, 193, 194, 201, 202, 206, 216-219] , mainly involving the phosphate oxygen atoms via bidentate NH⋯O⋯HN "phosphate clamps" [52, 186, 220] . ese were found to produce structural changes in DNA and key proteins which are different from those induced by currently used Pt-drugs (through conventional interactions), leading to a quite high cytotoxicity in several human cancer lines [52, 157, 186, 215] . In addition, TriplatinNC shows selectivity for DNA oxygen atoms and against DNA nitrogen atoms. e cellular uptake of these cationic nonreactive agents is remarkably enhanced relative to neutral cisplatin and cisplatin-like polynuclear complexes [157, 163, 188] , and it increases as the overall positive charge increases due to the weak molecular interactions on the cells' surface which leads to an increased bioavailability at the target. Additionally, this "noncoordinative" approach may help to decrease the toxic side effects of conventional platinum agents by minimising potentially deleterious parallel reactions. Accordingly, this kind of compounds may be able to circumvent the pharmacokinetic problems associated with sulphur deactivation of conventional Pt(II)-based drugs (e.g., by glutathione competition [221, 222] ), since no metal coordination to thiol groups can occur.
Recently, functionalized platinum agents have been developed, of general formula [PtL 3 (nucleobase)] n+ , L representing a linear polyamine ligand and the nucleobase being either guanine or cytosine based [223, 224] . 
Palladium for Platinum Substitution in Polyamine Complexes.
Although platinum(II) is a well-established pharmacophore for the development of cytotoxic agents [37, 225] , numerous Pt(II)-based chemotherapeutic strategies being reported to this date; its high thiophilicity is responsible for several severe drawbacks: drugs' inactivation and development of resistance via reaction with endogenous sulphur-containing biomolecules present in high concentrations inside the cell (e.g., cysteine and methionine-rich proteins, glutathione, metallothionein, and albumin [226] [227] [228] [229] [230] ) and high nephrotoxicity due to interaction with renal thiol enzymes [231, 232] .
Since palladium is known to bind strongly to DNA [233] , and in view of its signi�cantly resemblance to Pt(II) as to its structural and coordination behaviour, research has been pursued on the development of compounds having one or more Pd(II) centres as an alternative to Pt(II) [77, 87, 88, 93, 96, 97, 165, 168-170, 174, 175, 177-180, 234-248] . Careful design of palladium complexes may allow targeting strategies which will hopefully lead to different pro�les of drug activity and to lack of cross-resistance as compared with platinumbased agents. Adverse effects, namely, nephrotoxicity, were found to be reduced when substituting Pt(II) by Pd(II) and using strongly coordinating ligands such as polyamines, which are hardly displaced by sulydryl groups from key proteins for kidney function [249, 250] .
e main reason for having neglected palladium compounds in the search for new metal-based antitumor agents up to about three decades has been their high liability regarding ligand exchange (Pd(II) complexes are ca. 10 5 times more labile than their Pt(II) counterparts), as well as their ability to form predominantly trans isomers. Actually, a low antitumoral capacity has long been attributed to Pd(II) complexes due to the rapid hydrolysis of their leaving groups (e.g., Cl − ) in aqueous solution, yielding highly reactive species unable to reach their pharmacological target. Such features were in opposition to the commonly established structure-activity relationships (SARs) based on platinum cytostatics. However, the growing progress in anticancer chemotherapy has showed that these early SAR rules are not obeyed by numerous active platinum compounds. Furthermore, although it is generally accepted that the mode of action of Pd(II) complexes as cytotoxic agents is similar to that described for their structural Pt(II) analogues, it is unlikely that structure-activity relationships based on the latter can successfully be extended to Pd(II) systems, due to their difference in relative reactivity [251, 252] .
e much higher liability of Pd(II) complexes as compared to their Pt(II) counterparts-namely the fast hydrolysis of the leaving groups (e.g., Cl) in physiological medium and the rapid cis → trans isomerisation kinetics-is a drawback to their use as pharmaceutical agents, due to a possible deactivation by reaction with biomolecules other than DNA and to a lower stability of the corresponding drug-DNA adducts. Accordingly, the development of an efficient Pd(II) antitumor drug involves particular requisites: stabilisation by a strongly coordinated ligand (e.g., Ncontaining donor), coupled to a careful choice of leaving group(s) (reasonably nonlabile), in order to ensure the in vivo structural integrity of the compound for a long enough period to enable it to perform its therapeutic action.
ISRN Spectroscopy
Hence, Pd(II) chelates with linear polyamines deserve special attention, since, similarly to their Pt(II) counterparts, they are expected to couple a quite high stability (both kinetic and thermodynamic, due to chelation) to signi�cant antitumor properties in view of the possibility of formation of nonconventional interactions with DNA. In fact, as a so metal ion Pd(II) yields stable coordination compounds with nitrogen-containing ligands (preferred over oxygen), namely, with polydentate aliphatic amines [93, 95, 97, [252] [253] [254] [255] [256] (Table 2) . Particular care should be taken in choosing these chelating ligands, since their chemical characteristics have been shown to in�uence the stability and the selfassembly properties of the corresponding Pd(II) complexes (e.g., formation of oligomeric species) [97, 257] . Actually, it has been observed that the square-planar geometry typical of Pd(II) coordination compounds is slightly distorted according to the nature of the ligands. When these bear only ethylenic chains, the N-Pd-N bond angles within the complex are signi�cantly smaller than the ideal value (90 ∘ ), while replacement by longer chains (such as propylene) leads to more regular square coordination arrangements around the metal centre (with less steric hindrance), accompanied by a higher thermodynamic stability.
Among the Pd(II) coordination compounds with Nchelating amines, polynuclear Pd(II) agents with polyamines comprising N 2 and N 3 donor sets have been prepared with a view to enforce an effective coordination template around the ion and reported to display signi�cant cytotoxicity, oen coupled to a clear selectivity (Table 2) . Chelates with the biogenic amines spermidine (triamine) and spermine (tetramine) were newly synthetized and assessed as to their antitumor properties by Navarro-Ranninger and coworkers [169-171, 258, 259] , some of them having yielded lower ID 50 (inhibition dose 50) values when compared to cisplatin [169, 170] . More recently, their effect on several human cancer cell lines has been further evaluated [165, 168, 175, 180] and related to their conformational preferences at physiological conditions [174, 178, 179, 260, 261] . ese cationic polynuclear Pd(II) chelates comprise two or three cisplatin-like moieties linked by variable length aliphatic polyamines, in analogy to previously reported Pt(II) compounds [15, 81, 84-86, 90-97, 159, 165, 169, 170, 185-199, 201, 202, 234, 240-246, 262-280] . e DNA adducts yielded by these complexes were found to be nondirectional and mainly interstand (both short and long range). Similarly to their Pt(II) homologues, the presence of more than one metal centre is expected to enhance conformational changes in the double helix, and consequently the agent's antitumor activity, since the repair mechanisms are likely to be less efficient. Although they have shown to be promising agents both in vitro and in vivo, when compared to many platinum-based anticancer drugs, none of these compounds has yet entered clinical trials.
Aiming at overcoming cis → trans isomerisation around the metal ion, the presence of bidentate amines has been an almost constant feature of new Pd(II) agents [90, 94, 240, [281] [282] [283] [284] . Various chelating nonleaving groups have been evaluated, from amine neutral ligands such as ethylenediamine [262, 285, 286] and diaminocyclohexane (DACH) [240] to alkylaminophosphine oxides [274] , mercaptoimidazoles, and pyridine and pyrimidine derivatives [275, 276, 287] . Several strategies have therefore been attempted to imposing a lower liability to palladium(II) complexes, from the use of polydentate amines, for example, ethylenediamine [93, 95] , NH 3 and diaminocyclohexane [288] , or tetradentate phenanthroline-type N 4 ligands [289] to the combination of two distinct molecular sub units around a metal centre, for example, a diamine and a pyridine derivative [282] or tridentate NNS ligands [267] . As to the leaving groups, two chlorides, a nitrato or a chelating dicarboxylate moiety have yielded good results.
In Table 2 ).
The Structural Factor
4.1. Structure-Activity Relationships. e biological activity of a compound does not rely solely on its chemical properties, being strongly dependent on its structure and conformational preferences. e numerous studies performed to this date on platinum and palladium compounds evidence a clear relationship between antineoplastic activity and structure/conformational preferences, being recognised that a simple chemical modi�cation may drastically affect the drug's absorption and reactivity pro�le� solubility, pharmacokinetic behaviour, molecule's lipophilic versus hydrophilic character, acid-base equilibrium, biodistribution and intracellular activation kinetics, cellular uptake, DNA-binding properties, relative amount of intrastrand versus interstrand cross-links and degree of long-range interactions, and metabolising reactions possibly inducing toxicity and therefore limiting the clinical usefulness of the new drug (adsorption, distribution, metabolization, excretion, and toxicity behavior, ADMET). Hence, a rational design of such metal-based drugs can only be accomplished in the light of accurate structural information, at physiological conditions, allowing to understand the biological behaviour of these systems at a molecular level. A thorough conformational analysis must therefore be carried out, for both the complexes and their DNA adducts, in order to establish the highly sensitive structure-activity relationships that underlie and control the drug's properties and function (pharmacokinetic and pharmacodynamic pro�les). In addition, the design of new platinum and palladium drugs may envisage to functionalise DNA-binding modes, in order to achieve selectivity as well as enhanced cytotoxic ability (effective interaction with the target) coupled to a low toxicity (minimised interplay with other biomolecules) and a decreased acquired resistance (optimal bioavailability, maximum nonrepairable damaging effect).
erefore, suitable analytical techniques are required for an accurate preclinical screening of new therapeutic candidates, aiming at the rapid assessment of their safety and efficiency. Upon cellular uptake of Pt(II)/Pt(IV) or Pd(II) complexes and metabolization [290] , interaction with DNA-their recognised main biological target-is expected to occur, preferably through the adenine and guanine purine bases (via covalent binding to N 7 ), causing deleterious conformational rearrangements. For polynuclear chelates, and according to their stereochemistry, bifunctional adducts involving two adjacent nucleobases or two residues of the paired DNA strands can be formed [38] . However, details of this pharmacodynamic process are scarcely known. Moreover, the characterisation of the adducts formed between these metallochemotherapeutics and DNA has been one of the main goals within this �eld, with a view to determine the most favourable structural requirements for an enhanced activity. Consequently, and despite the high number of reported studies on platinum and palladium-based polyamine antitumor compounds, the relationship between their cytotoxicity and the nature of the ligand(s) and coordination pattern is the object of an intense research. When second-generation cisplatin-based drugs were �rst developed (in the 1980�s), a set of empirical rules was suggested in order to guarantee cytotoxicity [291, 292] : (i) at least two cis-coordinated amino donor groups (L, each carrying one or more NHR 2 residues), along with two cis anionic leaving groups (X, moderately bound)-yielding a cis-[PtL 2 X 2 ] con�guration; (ii) �ero total charge; (iii) Pt(II) as the metal centre. However, in the light of the current state of research, these are no longer considered as mandatory conditions for drug effectiveness, since many newly developed nonclassical platinum and palladium agents with promising anticancer activity do not conform to these early requisites [293] (Figure 7) . ree striking examples of rule breakers are: (i) the numerous trans complexes which have been found to display high cytotoxic capacity, both Pt(II) [81, 195, 197, 234, 287, [294] [295] [296] [297] and Pd(II) based, namely, trans platinum complexes with planar amine ligands (TPAs) [215, 234, 296, [298] [299] [300] ; (ii) the highly positively charged noncovalent backbone binders without hydrolysable groups, such as AH44 [186, 216] or TriplatinNC [52, 163, 186, 188-191, 193, 194, 201, 202, 217, 219, 220] ; (iii) numerous Pd(II) compounds, that have been veri�ed to act as efficient anticancer drugs [247] (Table 2) . Also, coordination compounds comprising only one amine ligand showed to be effective antineoplastic agents [293, 301] .
Accordingly, based on the general formula, cis-[PtX 2 (NHR 2 ) 2 ] (X = leaving group; R = organic coordinating group), the main factors presently considered determinant for a proper ADMET pro�le are (Figure 8 ) (i) number, oxidation state and type of the metal centre(s); (ii) chain length and number of coordinating amine groups of the nonlabile ligand(s), as well as �exibility and bulkiness (e.g., type of substituents and/or degree of branching); (iii) chemical characteristics of the amine linker(s) between metal ions (e.g., length/�exibility and hydrogen-bonding capacity); (iv) nature and relative orientation of the leaving groups; (v) type of axial groups, in Pt(IV) complexes; (vi) total charge. In polynuclear noncovalent complexes, substitution of the labile chlorides by inert NH 3 or alkylamine moieties leads to an overall high positive charge and allows preassociation of the complexes to the DNA helix prior to preassociation and backbone binding via phosphate clamps.
In summary, although no systematic pattern of structureactivity relationships is yet to be found, there are some activity-determinant geometrical and conformational parameters that should be considered in an amine-type ligand when designing novel metal-based antineoplastic agents (Figure 8 ), since they rule the effectiveness of the interplay between the resulting complex and its pharmacological target (DNA).
Vibrational Spectroscopy Studies.
A rational drug design strategy demands the preclinical screening of new candidates, for the assessment of their efficiency and safety. Regarding Pt(II) and Pd(II)-polyamine complexes, upon cellular uptake, drug activation via hydrolysis and interaction with DNA are expected to occur (covalent binding at the N 7 of guanine and adenine), causing deleterious conformational rearrangements and thus preventing DNA transcription and replication. Although details of these pharmacokinetic and pharmacodynamic processes are still not completely understood, they are known to be greatly determined by the compounds' structural and conformational preferences under physiological conditions. Consequently, previous knowledge of these characteristics is essential to accurately predict the biological behaviour of the newly designed agents. Although it is preferable, wherever possible, to determine structural parameters directly, via diffraction techniques, the lack of good quality crystals for this kind of inorganic compounds oen hinders this approach. Actually, both platinum and palladium amine complexes are very sensitive to preparative conditions and several forms are oen stabilised in the powders produced (polymorphism), such that single crystals are not easily obtained. Indeed, structural defects are typically found in this broad class of inorganic systems, which leads to failure of conventional diffraction techniques. e only crystal structures reported for Pt(II) drugs presently in clinical practice are those for cisplatin [302] and carboplatin [303, 304] . However, conventional diffraction methods cannot yield the hydrogen atom positions, which is a major drawback for interpreting biochemical mechanisms, that frequently rely on H-bond type close contacts.
Under these circumstances, spectroscopy offers numerous advantages, especially when modern ab initio quantum mechanical calculations can be exploited in order to predict the spectra of putative structures. Vibrational spectroscopic techniques, in particular, are particularly suited to this type of studies, since they yield unique �ngerprint data for each investigated compound, comprising detailed and reliable structural evidence, based on the analysis of the vibrational modes associated with each chemical group within the molecule. Access to the complete range of vibrational spectroscopy techniques-infrared (FTIR, Fourier transform infrared), Raman, and Inelastic neutron scattering (INS)-allow to record and analyse the full vibrational pro�le of the systems under study. Moreover, the combined use of dedicated state-of-the-art theoretical approaches (e.g., quantum mechanical calculations) leads to an accurate interpretation of the spectroscopic data, yielding the precise conformational pro�le of a compound, including the intraand intermolecular network of interactions (e.g., H-bonding) responsible for its structural preferences at physiological conditions [77, 174, 260, 261, 305] . Also, not only the free metal-based agent can be studied, but also its DNA adducts, under different pH and temperature conditions (mimicking the physiological media at distinct organs and tissues of interest) [179, [306] [307] [308] [309] [310] . In addition, the interplay with chosen biomolecules (e.g., glutathione, actin, human serum albumin, or hemoglobin [311, 312] ) or with membranes [313] can be investigated, as well as the drug's bioavailability (upon controlled delivery) and its effect at the subcellular level.
Raman, in particular, has been long recognised as a valuable tool in pharmaceutical and medicinal research [314] [315] [316] [317] , since it is noninvasive and can be reliably applied to both in vitro and in vivo conditions (with virtually no interference from water). Additionally, it may be coupled to microscopy and attain confocality (at a very high spatial resolution, ca. 200 nm), allowing the direct observation of living cells and their organelles [318] [319] [320] [321] and the detection of the compounds in the intracellular media (drug's bioavailability and localisation) [318, 322, 323] . is capability has recently been exploited in order to determine distinct cell states such as viability, apoptosis, or necrosis [324, 325] and to differentiate normal from abnormal, drug resistant from nonresistant, or healthy from diseased cells [326] [327] [328] [329] , as well as to monitor processes as the intracellular uptake of drugcarrier systems [330] , drug permeation through the human skin [331, 332] , or cellular response to drugs (e.g., cisplatin) and stress factors [333] [334] [335] [336] . Additionally, the combination of infrared spectroscopy and microscopy, developed during the last decade, has led to signi�cant advances in tissue and cellular characterisation. In sum, coupling vibrational and microscopic techniques presents the advantage of allowing not only the determination of the structural characteristics of potential pharmacological agents, but also to determine their effect on living samples, either cells or tissues [332, 337, 338] , both growth inhibiting in diseased (neoplastic) cells and toxic (deleterious side-effects) in healthy cells.
Inelastic neutron scattering spectroscopy, in turn, allows the observation of the low frequency vibrations of the complexes that encompass most of the modes associated with the metal (e.g., metal-ligand interactions in the free drug or metal-DNA bonds within the adducts). ese are extremely difficult to observe with optical vibrational techniques (either Raman or FTIR) and are therefore usually unavailable except through INS. Furthermore, the technique is particularly well suited to the study of hydrogenous compounds, and the connection between the measured INS spectrum and that calculated by quantum mechanical techniques is quantitative and quite straightforward, enabling a reliable assignment of the experimental data and an accurate association to structural features. Hence, the combined application of the complementary FTIR, Raman, and INS spectroscopic techniques, coupled to dedicated theoretical methodologies, allows a thorough structural analysis of platinum and palladium polyamine complexes, yielding such relevant information as structure and conformational preferences, as a function of pH, ionic strength, and temperature. When coupled to biological screening experiments, this approach connects molecular geometry to pharmacological activity, in a reliable and unequivocal manner. e platinum drugs currently used in the clinic have been the object of conformational analysis through vibrational spectroscopy techniques and theoretical methods. Cisplatin, in particular, has been extensively studied as to its conformational preferences, mainly by infrared and Raman techniques. ree conformers have been identi�ed-only one is stable at physiological conditions [260, 261, [339] [340] [341] -as well as two polymorphic species, and [342] . A combined infrared, Raman, and INS study of cisplatin, in turn, has allowed the complete assignment of the vibrational features of the drug, through the observation of the whole spectral window of interest [305] . In addition, the pharmacokinetic behaviour of the drug has been investigated, namely, its intracellular hydration process which is known to be the main drug activation step [343] . Regarding the second-generation Pt(II) drugs, the most stable geometry was determined for both carboplatin [341, 344] and oxaliplatin [345] , as well as their ligand exchange kinetics (at physiological conditions).
Many cisplatin-like complexes, both Pt(II) and Pd(II), have been investigated as to their structural and conformational behaviour by vibrational methods coupled to theoretical approaches-quantum mechanical calculations, mostly at the Density Functional eory (DFT) level [174, 181, 260, 261, 305, 314, 346] (Table 3) . Among these, di-and trinuclear platinum and palladium chelates with linear (including biogenic) amines [178, 181] and their modi�ed homologues [77] were studied, leading to a better understanding of their interaction with DNA [179] . Apart from the structural analysis of the metal-based agent, the entities resulting from its interplay either with the target (DNA bases, mainly guanine and adenine) [179, [306] [307] [308] [309] [310] or with other biomolecules [311] [312] [313] are essential, and once more vibrational spectroscopy is the technique of choice for attaining a thorough conformational picture of these adducts. Raman is especially useful, as it allows the study under physiological conditions, that is, considering an aqueous medium at de�ned temperature, pH, and ionic strength values.
Apart from vibrational methods, techniques such as EXAFS (extended X-ray absorption �ne structure) spectroscopy are also very suitable for a thorough characterisation of metal-based potential drugs, since they are capable of yielding detailed information on the local atomic structure around the metal centre in this kind of inorganic noncrystalline materials [347] [348] [349] : either in the complexes, in their DNA adducts (where the hydrolysable ligands are substituted by one or more nitrogens from the purine bases) or in molecular associations with other biomolecules (such as glutathione) that may be involved in parallel reactions with the drug. State-of-the-art techniques such as synchrotron radiation-EXAFS greatly increases the quality of the results, due to the high brightness of the synchrotron radiation sources as compared to conventional ones-several orders of magnitude brighter than X-ray tubes-ensuring quick (as short as several milliseconds) EXAFS-spectrum measurement for very low densities of an element [350] .
When combined with cytotoxicity screening assays, these spectroscopic studies aim at gathering reliable data on the SARs ruling the antineoplastic properties of cisplatin-like complexes, allowing a tailored design of novel polynuclear Pt and Pd polyamine anticancer agents, displaying an improved efficiency and a diminished toxicity.
Conclusions and Future Trends
Although metallopharmaceuticals are still a minor proportion of the currently marketed drugs, the elucidation of their mechanism of action will greatly contribute to the development of improved pharmacophores, with an enhanced cytotoxic capacity, namely, towards chemotherapy-insensitive tumours, coupled to a lower toxicity and a decreased acquired resistance. In order to achieve this goal, two main factors must be explored: (i) the strict and very sensitive relationship between structure/conformation and activity; (ii) use of delivery vehicles for controlling drug release and targeting (e.g., liposome encapsulation or use of speci�cally designed polymers). Changes in pharmaceutical formulations for achieving a customised release lead to an improved drug stability, an enhanced in vivo bioavailability and a higher degree of DNA complexation, directly correlated to a more efficient anticancer capacity. Despite the intense efforts placed in this �eld for the forty years since the discovery of cisplatin, only 6 Pt drugs have gained marketing approval, while 14 were dropped during clinical trials.
e platinum-based compounds, either in clinical use or under clinical trials, share a common chemical structure: amine carrier ligands and chloride, nitrate, or dicarboxylate leaving groups. Research has shied from mono-to polynuclear complexes with polyamine ligands (namely, linear alkylamines), aiming at a more effective DNA platination and an increased and less-repairable damage, as well as from platinum to palladium agents. In particular, polynuclear Pt(II) or Pd(II) chelates, containing two or three cisplatin-like metal centres and variable length polyamines as bridging linkers, constitute a group of new-generation drugs of great potential clinical importance-either coordinative compounds (yielding covalent adducts with DNA) or noncovalent, electrostatic backbone binders.
At present, reliable structure-activity relationships have been established for platinum and palladium amine antineoplastic agents, which constitute a precious contribution for attaining optimised chemopharmaceuticals. ese extend beyond the previously accepted structural rules, in some cases even contradicting these, and can be summarised as follows: (i) polynuclear complexes (as compared to mononuclear homologues) are capable of an enhanced association with DNA bases (thus leading to an increased damage); (ii) alkylpolyamine bridging units with a long enough chain to render considerable �exibility allow the formation of longrange interstrand adducts with DNA, as opposed to short monodentate amine ligands; (iii) noncovalent interactions with DNA, by polycationic Pt(II) or Pd(II)-polyamine complexes, may be as effective as polynuclear cisplatin-like covalent binders; (iv) chloride or oxygen-containing hydrolysable groups modulate the kinetics of intracellular drug activation (via hydrolysis); (v) Pd(II) centres are responsible for an efficient interplay with DNA, leading to a quite high cytotoxicity with diminished side effects (e.g., parallel reactions with sulphur-containing biomolecules).
In this search for structurally new platinum and palladium polyamine complexes with suitable pharmacological properties, a molecular approach has been lately applied in which the search for more effective modes of interaction with DNA is based on the study of the structural features and conformational behaviour of the compounds, which are tailored according to the desired biological role-optimisation of their interaction with the therapeutic target. is kind of rational approach for the design of nextgeneration chemotherapeutics relies on the establishment of reliable SARs, that are of the utmost relevance in order to modulate the newly developed agent's activity-optimising the pharmacophore and minimising the toxicophore. Spectroscopic techniques, particularly vibrational spectroscopy, have succeeded in establishing a reliable connection between structure and function, through an accurate conformational analysis of the potential pharmacological agents. Hence, vibrational spectroscopy is presently undergoing a real boost, with its application to medicinal chemistry and pharmacology.
In summary, the development of improved platinum and palladium-based polyamine anticancer agents relies on a target-directed tailored drug design, with an emphasis on controlled delivery, as well as on drug repro�ling, with a view to enhance and extend cytotoxic activity with minimal toxicity [145, 146, [351] [352] [353] [354] . Such an approach depends on accurate methods for determining structural and conformational behaviour, as well as for probing interaction with biological receptors and vibrational spectroscopy (preferably combining optical and acoustic techniques) being an invaluable tool in drug design.
